Literature DB >> 745589

Increasing incidence of Gram-positive sepsis in cancer patients.

P A Pizzo, S Ladisch, R M Simon, F Gill, A S Levine.   

Abstract

A review of the agents causing septicemia in cancer patients during a nine-year period (1968--76) revealed that Gram-positive organisms (especially S aureus) have become the most frequent isolates during the last two years. This unanticipated increase (P less than 0.001) in the number of Gram-positive isolates could not be related to horizontal transmission nor to changes in patient characteristics or therapy.

Entities:  

Mesh：

Year:  1978        PMID： 745589     DOI： 10.1002/mpo.2950050133

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN： 0098-1532


  17 in total

1.  Changes in the spectrum of organisms causing bacteremia and fungemia in immunocompromised patients due to venous access devices.

Authors:  T E Kiehn; D Armstrong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

2.  Febrile neutropenic events in cancer patients: treatment for fever and neutropenia in young adult patients during intensive chemotherapy for solid tumours.

Authors:  M Nobbenhuis; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 3.  Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy.

Authors:  J W Hathorn; M Rubin; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

4.  Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.

Authors:  E R Broun; J L Wheat; P H Kneebone; K Sundblad; R A Hromas; G Tricot
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 5.  Bacteremia and fungemia in the immunocompromised patient.

Authors:  T E Kiehn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

6.  Ceftazidime does not enhance cyclosporin-A nephrotoxicity in febrile bone marrow transplantation patients.

Authors:  C Verhagen; B E de Pauw; T de Witte; R S Holdrinet; J T Janssen; K J Williams
Journal:  Blut       Date:  1986-10

7.  Three-step empiric treatment for severely neutropenic patients with fever: ceftazidime--vancomycin--amphotericin B.

Authors:  H Koeppler; K H Pflueger; R Seitz; K Havemann
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

8.  Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin.

Authors:  H F Guiot; W G Peters; P J van den Broek; J W van der Meer; J A Kramps; R Willemze; R van Furth
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

9.  Emergence of MRSA in positive blood cultures from patients with febrile neutropenia--a cause for concern.

Authors:  Patrick G Morris; Tidi Hassan; Mairead McNamara; Astrid Hassan; Rebecca Wiig; Liam Grogan; Oscar S Breathnach; Edmond Smyth; Hilary Humphreys
Journal:  Support Care Cancer       Date:  2008-02-15       Impact factor: 3.603

10.  Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy. For the treatment of febrile episodes in neutropenic patients.

Authors:  J A Paladino; L D Fong; A Forrest; R Ramphal
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.